Hepatitis B reactivation during everolimus treatment. En savoir plus sur Hepatitis B reactivation during everolimus treatment.
Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study. En savoir plus sur Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study.
Curcumin dietary supplements and everolimus-based cancer treatment. En savoir plus sur Curcumin dietary supplements and everolimus-based cancer treatment.
Everolimus induced mood changes in breast cancer patients: a case-control study. En savoir plus sur Everolimus induced mood changes in breast cancer patients: a case-control study.
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. En savoir plus sur Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Phase I safety pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480) an oral pan-HER receptor tyrosine kinase inhibitor in patients with advanced solid tumors. En savoir plus sur Phase I safety pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480) an oral pan-HER receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
Four-arm robotic lung resection versus muscle-sparing mini-thoracotomy: retrospective experience. En savoir plus sur Four-arm robotic lung resection versus muscle-sparing mini-thoracotomy: retrospective experience.
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. En savoir plus sur Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.